Eupraxia Pharmaceuticals (NASDAQ:EPRX) Coverage Initiated at Craig Hallum

Research analysts at Craig Hallum initiated coverage on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) in a note issued to investors on Friday, MarketBeat.com reports. The brokerage set a “buy” rating and a $12.00 price target on the stock. Craig Hallum’s target price would suggest a potential upside of 228.77% from the company’s previous close.

A number of other equities research analysts have also recently issued reports on EPRX. Rodman & Renshaw began coverage on shares of Eupraxia Pharmaceuticals in a research note on Thursday, November 14th. They issued a “buy” rating and a $9.00 price objective for the company. RODMAN&RENSHAW raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, November 14th.

Eupraxia Pharmaceuticals Price Performance

EPRX stock opened at $3.65 on Friday. Eupraxia Pharmaceuticals has a one year low of $2.20 and a one year high of $5.15. The stock has a market cap of $130.12 million and a PE ratio of -5.07. The firm has a 50 day simple moving average of $3.13 and a two-hundred day simple moving average of $2.91.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

A number of institutional investors have recently made changes to their positions in EPRX. Millennium Management LLC bought a new stake in Eupraxia Pharmaceuticals during the 4th quarter valued at $31,000. Raymond James Financial Inc. bought a new stake in Eupraxia Pharmaceuticals during the 4th quarter valued at $37,000. Finally, Bank of Montreal Can raised its holdings in Eupraxia Pharmaceuticals by 15.2% during the 4th quarter. Bank of Montreal Can now owns 56,750 shares of the company’s stock valued at $178,000 after buying an additional 7,500 shares during the last quarter.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.